--- schema_version: "secwatch.filing_event.v1" accession: "0001104659-22-113964" form_type: "8-K" ticker: null cik: "0001709401" company_name: "Rubius Therapeutics, Inc." filed_at: "2022-11-02T23:59:59+00:00" generated_at: "2026-06-22T14:38:59.190148+00:00" event_type: "other_material" sentiment: "negative" materiality_score: 1.0 calibrated_materiality_score: 1.0 confidence: "high" source: SEC EDGAR --- # Rubius cuts 82% of staff, CEO and CFO exit, begins strategic review ## Summary - Terminated 42 employees (82% of workforce); expects ~$4.4M in Q4 2022 severance charges. - CEO Pablo Cagnoni, CFO Jose Carmona, and CLO Maiken Keson-Brookes step down effective Nov 15, 2022. - Dannielle Appelhans appointed CEO/President and interim CFO; her employment expected to end Jan 31, 2023. - Board approved plan to review strategic alternatives, including sale or merger of the company. - Recent termination of $75M credit facility with SLR Investment Corp. cited as factor in financial condition. ## SEC filing metadata - accession: 0001104659-22-113964 - form_type: 8-K - cik: 0001709401 - company_name: Rubius Therapeutics, Inc. - filed_at: 2022-11-02T23:59:59+00:00 - event_type: other_material - sentiment: negative - materiality_score: 1.0 - calibrated_materiality_score: 1.0 - confidence: high - sec_items: 2.05, 5.02 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1709401/000110465922113964/0001104659-22-113964-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1709401/000110465922113964/tm2229359d1_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001104659-22-113964 - JSON: https://secwatch.observer/filing/0001104659-22-113964.json - Plain text: https://secwatch.observer/filing/0001104659-22-113964.txt ## Key facts - Executive change Dannielle Appelhans was appointed as Interim Chief Financial Officer and Principal Accounting Officer at Rubius Therapeutics, Inc.. - Action: will serve as - Role: Interim Chief Financial Officer and Principal Accounting Officer source text: Ms. Appelhans will also serve as the Company’s principal executive officer, and as its interim principal financial officer and principal accounting officer. evidence_url: https://www.sec.gov/Archives/edgar/data/1709401/000110465922113964/0001104659-22-113964-index.htm - Executive change Pablo J. Cagnoni was appointed as Chairman of the Board at Rubius Therapeutics, Inc.. - Action: appointed - Role: Chairman of the Board source text: Dr. Cagnoni will continue in his role as a member of the Board, and was appointed to serve as Chairman of the Board, effective November 1, 2022 evidence_url: https://www.sec.gov/Archives/edgar/data/1709401/000110465922113964/0001104659-22-113964-index.htm - Executive change Dannielle Appelhans was appointed as Chief Executive Officer and President at Rubius Therapeutics, Inc.. - Action: appointed - Role: Chief Executive Officer and President source text: the Board has appointed Dannielle Appelhans, age 39, Chief Operating Officer of the Company, as the Company’s Chief Executive Officer and President, effective upon the Separation Date evidence_url: https://www.sec.gov/Archives/edgar/data/1709401/000110465922113964/0001104659-22-113964-index.htm - Executive change Maiken Keson-Brookes departed as Chief Legal Officer at Rubius Therapeutics, Inc.. - Action: stepped down - Role: Chief Legal Officer source text: Maiken Keson-Brookes, Chief Legal Officer and corporate secretary of the Company, have negotiated a separation of service with the Company, effective November 15, 2022 evidence_url: https://www.sec.gov/Archives/edgar/data/1709401/000110465922113964/0001104659-22-113964-index.htm - Executive change Noubar Afeyan resigned as Chairman of the Board at Rubius Therapeutics, Inc.. - Action: resigned - Role: Chairman of the Board source text: Dr. Noubar Afeyan, Chairman of the Board of Rubius, resigned from the Board and will continue as a Board observer. evidence_url: https://www.sec.gov/Archives/edgar/data/1709401/000110465922113964/0001104659-22-113964-index.htm - Restructurings & Charges Rubius Therapeutics, Inc. announced a restructuring with charges of approximately $4.4 million (42 of its employees (representing 82% of its current employee base)). - Type: restructuring - Charge: approximately $4.4 million - Headcount: 42 of its employees (representing 82% of its current employee base) source text: On November 2, 2022, Rubius Therapeutics, Inc. (the “Company”) announced that, in light of the Company’s financial condition, including the recently disclosed repayment and termination of its $75 million credit facility with SLR Investment Corp., and the early stage of its programs, its Board of Directors (the “Board”) approved a plan to review strategic alternatives, including a sale or merger of the Company or one or more sales of its assets, and to significantly and immediately reduce its operations (the “Plan”). In connection with this Plan, the Company has terminated 42 of its employees (representing 82% of its current employee base), leaving a core team of individuals to lead the strategic review process. The Company expects that these measures will reduce its operating expenses with the goal of allowing the Company to pursue any viable strategic alternatives. As a result of the Plan, the Company estimates that it will incur charges of approximately $4.4 million in the fourth qua evidence_url: https://www.sec.gov/Archives/edgar/data/1709401/000110465922113964/0001104659-22-113964-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.